Speaking to management, I am led to believe that HCL will not appeal the decision (do not hold me to this). Hopefully onwards and upwards.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025